A WSI analysis algorithm designed to segment and quantify NP-Tau immunoreactivity demonstrated lower temporal neocortical NP-Tau density in the PRIME LTE Patient compared to the range of the cohort of HIGH AD case controls (Fig. 4e). The gene discussed is MAPT; the disease is Alzheimer disease.